New AI programming language goes beyond deep learning

June 27, 2019 Vijay Soni 0

New AI programming language goes beyond deep learning By: Rob Matheson | MIT News Office A team of MIT researchers is making it easier for novices to get their feet wet with artificial intelligence, while also helping experts advance the field. In a paper presented at the Programming Language Design and [..]

Adeptrix Corporation Receives Funding from ICV Venture Engineering Fund I to Accelerate Product Development Pipeline and Advance Translational Research Biology

May 9, 2019 Jeffrey C. Silva 0

Adeptrix Corporation Receives Funding from ICV Venture Engineering Fund I to Accelerate Product Development Pipeline and Advance Translational Research Biology By: Jeffrey C. Silva, Ph. D. | Adeptrix Beverly, MA 01915, May 6th, 2019, Adeptrix Corporation announces the completion of initial investment through ICV Venture Engineering Fund I, for its [..]

Assessing the Place Of AI in the Human Workplace

May 3, 2019 Nick Galov 0

Assessing the Place of AI in the Human Workplace By: Nick Galov For years, pop culture has painted AI as an autonomous technology that is built to help mankind but often ends up hurting it instead. As modern technology continues to steer closer towards realizing AI’s full potential, there are [..]

What is Quantum Computing?

February 21, 2019 Aysha Naurein 0

What is Quantum Computing? By: Aysha Naurein Computers have today become so common that it would be difficult for us to think of a life devoid of them. It helps us do a lot of work simultaneously, quickly, effectively and has made life a lot easier. There are better versions [..]

AI, the Law, and Our Future

January 23, 2019 Vijay Soni 0

AI, the Law, and Our Future By: Peter Dizikes | MIT News Office Scientists and policymakers converged at MIT on Tuesday to discuss one of the hardest problems in artificial intelligence: How to govern it. The first MIT AI Policy Congress featured seven panel discussions sprawling across a variety of [..]

FDA Approved Firdapse® :First  Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

December 5, 2018 Vijay Soni 0

FDA Approved Firdapse® :First  Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) By: Catalyst Pharmaceuticals, Inc. NEWS Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® [..]

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease

November 23, 2018 Vijay Soni 0

Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease By: Novartis News Novartis announced today that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both [..]

FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia

November 22, 2018 Vijay Soni 0

FDA Grants Accelerated Approval to Genentech’s Venclexta® for Acute Myeloid Leukemia By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Venclexta® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or [..]

Sandoz Receives FDA Approval for Biosimilar HyrimozTM

October 31, 2018 Vijay Soni 0

Sandoz Receives FDA Approval for Biosimilar HyrimozTM By: Novartis News Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients [..]

National Fellowships for Graduates/Post Graduates Students, India :2

October 25, 2018 Richa 0

National Fellowships for Graduates/Post Graduates Students, India :2 By: Dr. Richa Lakhotia Here is the remaining list of all other fellowships.  14. Postdoctoral Fellowships in Physics at Harish-Chandra Research Institute in India, 2018 The Harish-Chandra Research Institute is delighted to offer its postdoctoral fellowships in Physics for Indian students. The fellowships [..]

National Fellowships for Graduates/Post Graduates Students, India :1

October 23, 2018 Richa 0

National Fellowships for Graduates/Post Graduates Students, India | TOC 1 By: Dr. Richa Lakhotia There are many exciting programs and funding opportunities to support graduates/post graduates students in India. Check out these fellowships available for indian students with varying academic backgrounds.  (1) Extra Mural Research Funding (Individual Centric) Individual centric competitive mode of [..]

Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer

September 30, 2018 Vijay Soni 0

Libtayo® Received FDA Aproval As First And Only Treatment For Second Most Common Skin Cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery [..]

FDA Approved the First and Only Therapy for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease

September 30, 2018 Vijay Soni 0

FDA Approved the First and Only Therapy for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE® (amikacin liposome inhalation suspension) for the [..]

FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease

August 10, 2018 Vijay Soni 0

FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease By: Alnylam News Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment [..]

New Era for Migraine Patients: EU Approved Aimovig® of Novartis

August 1, 2018 Vijay Soni 0

New Era for Migraine Patients: EU Approved Aimovig® of Novartis   Novartis announced that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed for migraine prevention to be approved [..]

EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana

July 17, 2018 Vijay Soni 0

EPIDIOLEX®:First FDA-approved Drug Derived From Marijuana GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration [..]

FDA Approves TPOXX® :The First Drug For Smallpox

July 17, 2018 Vijay Soni 0

FDA Approves TPOXX® :The First Drug For Smallpox SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule [..]

FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq

May 7, 2018 Vijay Soni 0

FDA Grants Priority Review to Genentech’s Cancer Immunotherapy Tecentriq By: Genentech News Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination [..]